"It is very pleasing to engage Daniel Brodén on a full-time basis. His previous experience from Swedish growth companies combined with his already extensive knowledge and commitment in Cereno makes him an ideal candidate to take the position as CFO. As the development work intensifies with preparations for the Phase 2 study with CS1 as well as the collaboration with Emeriti Bio begins to continue the development of the newly acquired preclinical substance CS014 (previously EB014), the Company needs a CFO dedicated to the financial development of Cereno Scientific. During his time as acting CFO, Daniel has played a major role in the work of ending the previous financing solution with convertible loans and has taken an active role in the work on the present rights issue. Daniel Brodén will be a key person for, among other things, our financing activities during this intense period of the company's development we are now entering," says Cereno Scientific's CEO Sten R. Sörensen.

Daniel Brodén has a Bachelor's degree in Business and Economics from Uppsala university and a Master's degree in Accounting from University of Gothenburg. Previously, he has been the financial manager for GU Ventures portfolio companies and has also worked as an auditor at Frejs Revisorer and at PwC's Financial services department.

"Im looking forward to work with Cereno Scientific on a full-time basis and continue the development work that I have been involved in as acting CFO. Furthermore, I am positive about the financial restructuring that we have now initiated and are pleased with the opportunity to see how the effects are met in the foreseeable future. Cereno Scientific has great ambitions and an interesting pipeline with great potential and we have a very exciting journey ahead of us," says Cereno Scientific's newly appointed CFO Daniel Brodén.

For further information, please contact:
Sten R. Sörensen - CEO
Tel: +46 733 74 03 74
E-mail: sten.sorensen@cerenoscientific.com
www.cerenoscientific.se

About Cereno Scientific AB
Cereno Scientific is developing a novel preventive medicine to treat thrombosis-related disease, based on the body's own intelligent clot-busting system. Cardiovascular disease is currently the leading cause of death worldwide. Current therapies are connected to an increased risk of bleeding and, as a result, low effectiveness due to lower dosing levels. In turn, this leads to a high risk of new blood clots. Cereno Scientific's drug candidate, CS1, is expected to provide a possibility for an effective prevention of thrombosis and a lower risk for serious bleeding complications than with current blood thinning therapies. CS1 is an innovative controlled release formulation of a known compound, and as such is expected to have a relatively short development time. The Gothenburg-based company is located in AstraZeneca's BioVenture Hub (http://www.azbioventurehub.com/) and is supported by GU Ventures (http://ventures.gu.se/). Cereno Scientific's B share has been listed on Spotlight Stock market since June 2016 with the ticker CRNO B, ISIN SE0008241558.